S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed soft tissue sarcoma of 1 of the following histologies:
• * Angiosarcoma, cutaneous or visceral
• * Malignant hemangiosarcoma
• * Malignant hemangiopericytoma
• * Grade 3-4 leiomyosarcoma
• * Grade 3-4 liposarcoma
• Must have evidence of unresectable residual disease, metastatic disease, or recurrent disease by radiography
• Measurable disease by x-ray, scans, or physical examination
• Archived paraffin-embedded tumor sections available
• No known brain metastases
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• Zubrod 0-1
• Life expectancy
• Not specified
• Hematopoietic
• WBC ≥ 3,000/mm\^3
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hepatic
• SGOT and SGPT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if due to liver metastases)
• Bilirubin normal (≤ 2.5 times ULN if due to liver metastases)
• PT, PTT, and INR normal
• Renal
• Creatinine normal OR
• Creatinine clearance ≥ 60 mL/min
• Cardiovascular
• No history of thromboembolic disease
• No uncontrolled hypertension
• Other
• Not pregnant or nursing
• Fertile patients must use effective contraception
• Able to swallow oral medication
• No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• At least 28 days since prior chemotherapy (42 days for carmustine or mitomycin) and recovered
• Prior adjuvant chemotherapy allowed
• No more than 1 prior chemotherapy regimen for metastatic disease
• Endocrine therapy
• Not specified
• Radiotherapy
• At least 28 days since prior radiotherapy and recovered
• * Must have evidence of disease progression within, or measurable disease outside of, the radiation field after completion of radiotherapy
• Surgery
• At least 28 days since prior major surgery and recovered
• Other
• No prior sorafenib
• No prior inhibitor of VEGFR or MAPK pathway
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No other concurrent investigational agents
• No concurrent therapeutic anticoagulation
• No concurrent administration of any of the following medications:
• * Rifampin
• * Hypericum perforatum (St. John's wort)
• * Cytochrome P450 enzyme-inducing antiepileptic drugs, including any of the following:
• * Phenytoin
• * Carbamazepine
• * Phenobarbital